Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Treatment regimens administered post-CAR T-cell therapy progression/relapse.
| Treatment Regimen | Number of Patients |
|---|---|
| Rituximab/obinatuzumab + bendamustine + polatuzumab | 11 |
| Lenalidomide + ibrutinib | 1 |
| Lenalidomide + tafasitamab | 1 |
| Loncastuximab | 2 |
| Pembrolizumab | 1 |
| Ibrutinib-based | 1 |
| Venetoclax-based | 1 |
| Chemoimmunotherapy, other | 8 |
| Radiation therapy | 6 |
| Clinical trial, cellular therapy | 5 |
| Clinical trial, other | 2 |
| Allogeneic hematopoietic stem cell transplant | 1 |
